Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on May 30, 2019. The registrant is a Delaware corporation with principal executive offices in Boston, Massachusetts, and its common stock trades on the NASDAQ Global Market under the symbol ZFGN. The filing serves as a Regulation FD disclosure regarding a regulatory update for the company's product candidate, ZGN-1061.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is a regulatory update concerning the product candidate ZGN-1061. The specific details of this update are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook projections, or a detailed discussion of risks and contingencies beyond the regulatory update. Management commentary is limited to the issuance of the press release regarding ZGN-1061.
Investor Verification Checklist
- Verify the specific content of the regulatory update for ZGN-1061 by reviewing the press release attached as Exhibit 99.1.
- Confirm the company name is Zafgen, Inc. (ZFGN), as the input metadata incorrectly referenced Larimar Therapeutics, Inc.
- Check subsequent filings for any financial impact resulting from the regulatory update on ZGN-1061.